We are Associate Sponsors at the FT Live: Pharma and Biotech Summit 2026

Forvis Mazars is a leading global professional services network specialising in audit and assurance, tax, advisory and consulting services. With more than 40,000 professionals across 100+ countries and territories, we combine global reach with deep sector expertise to support clients through complex business, regulatory and market challenges.

Meet our pharma and life sciences team

Present throughout both days of the summit, our pharma and life sciences specialists work with businesses across the sector, from emerging biotech and high-growth innovators to established pharmaceutical groups, investors and organisations operating across the wider healthcare ecosystem. Drawing on deep sector knowledge and international experience, we help clients respond to regulatory change, strengthen operations, manage risk and translate innovation into sustainable commercial growth.

Whether you're scaling an emerging business, pursuing investment or transactions, entering new markets, transforming operations or navigating an increasingly complex risk and regulatory environment, our experts will welcome the opportunity to connect with you to discuss:

• Operational resilience and efficiency transformation
• Technology and AI
• Tax, audit, assurance and financial reporting
• Investment, fundraising, transactions and deal readiness
• Governance, regulatory compliance and enterprise risk 
• Growth strategy, market entry and international expansion

Visit our stand during the summit to discuss the challenges and opportunities shaping your organisation, and how we can help prepare for what’s next.

Join our panel discussion:  China 2035 - the next chapter in a global pharma power

Our Partner and Head of Pharma & Life Sciences, Nigel Layton, will join a panel of industry experts to explore China’s growing influence on the global pharma landscape and what its next phase of development could mean for businesses, investors and markets worldwide.

The discussion will consider key questions including:

• Which of China’s strengths are hardest to match: speed, scale, trial execution, scientific depth or deal flow?
• What are the keys to successful partnerships with Chinese companies, and how different are the main risks around site quality, data integrity and ethics from those in other markets?
• As US-China tensions rise, does Europe move closer to China, or risk being left behind if it cannot move faster and cut costs?
• What will it take for more Chinese companies to build global blockbusters, global brands and lasting commercial presence outside China?

Speakers

Nigel Layton  Group Head of Life Sciences, Forvis Mazars

Cui Cui  Managing Director  and Head of Asia Healthcare, Jefferies

Kenneth Sun  Head of Asia, Royalty PharmaPharma

Hoyin Lam Director, Search & Evaluation – Oncology,  R&D Business Development, GSK

Moderator: Drew Armstrong  Executive Editor, Endpoints New